TRDA
Entrada Therapeutics, Inc.
NASDAQ · USHealthcareBiotechnology
$6.34-7.98%
Price as of Jul 20, 2026
TRDA growth
Entrada Therapeutics, Inc. growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- -96.7%
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
- Revenue
- +184.5%
- EBITDA
- +102.5%
- EPS
- +48.7%
Three-year CAGR
- Revenue
- -55.6%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- —
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.